Analyst firms · Citigroup · MRK

Citigroup MRK price target and rating history

Merck & Company Inc. (MRK) · Health Care

Citigroup rates Merck & Company Inc. (MRK) Neutral with a $125 price target, as of its latest action on May 6, 2026. It has published 5 rating actions on MRK since November 2021, including 1 upgrade and 2 downgrades. Across 11 firms with a MRK price target in the last 12 months, the median target is $140. Citigroup's $125 is 11% below that.

Current rating
Neutral
Price target
$125
Median target, all firms
$140
Actions on MRK
5

Citigroup price target on MRK

$130$107$8420222023202420252026
Citigroup price target on MRK, each point a stated target, November 2021 to May 2026.

Every Citigroup rating on MRK

How other firms rate MRK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
DZ BankHold$153Nov 3, 2026
RBC Capital MarketsSector Perform$150Aug 20, 2026
Morgan StanleyOverweight$179Aug 20, 2026
DaiwaOutperform$143Aug 12, 2026
CitigroupNeutral$125May 6, 2026
BarclaysOverweight$140Feb 20, 2026
Deutsche BankBuy$150Feb 13, 2026
Wolfe ResearchOutperform$135Jan 8, 2026
BMO Capital MarketsOutperform$130Dec 18, 2025
Wells FargoOverweight$125Nov 24, 2025
ScotiabankSector Outperform$105Nov 13, 2025

Questions about Citigroup and MRK

What is Citigroup's price target for MRK?
Citigroup's latest stated price target for Merck & Company Inc. (MRK) is $125, from its action on May 6, 2026.
What is Citigroup's rating on MRK?
Citigroup rates MRK Neutral, a neutral rating, as of May 6, 2026.
When did Citigroup last change its view on MRK?
On May 6, 2026, Citigroup resumes coverage at Neutral, price target $125.
How does Citigroup's MRK target compare with other analysts?
Across 11 firms with a MRK price target in the last 12 months, the median target is $140. Citigroup's $125 is 11% below that.

More MRK rating histories

All Citigroup ratingsMRK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.